06-18-2020 | ADA 2020 | Conference coverage | Video
Expert commentary: The VERTIS-CV trial
Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).
06-16-2020 | ADA 2020 | Conference coverage | Video
Researcher comment: The VERTIS-CV trial
Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).
Medicine Matters conference coverage is brought to you in partnership with medwireNews
ada2021Header/© rocketclips/ stock.adobe.com; dragana991 / Getty Images / iStock, Cardiovascular disease (illustration)/© psdesign1/fotolia.com, Tablet device showing the chemical structure of Metformin/© Zerbor / Fotolia, Boy checks glucose (illustrative with model)/© FatCamera / Getty Images / iStock, AdobeStock_104219176/© naftizin / stock.adobe.com, Blood sugar check in pregnancy/© Jovanmandic / Getty Images / iStock, Abbott Freestyle Libre/© Abbott Diabetes Care, Medicine Matters diabetes Editorial Board, Rayhan Lal, Francesco Giorgino, Chris Cannon, Matthew Crowley, John Wilding, Jay Shubrook